Chinese biotechnology services (08037.HK) expects the mid-term net loss attributable to shareholders to decrease by approximately 59% year-on-year.

The Zhitong Financial APP News reported that China Biotech Services (08037.HK) announced that the company's anticipated attributable loss to owners during the mid-term period of 2025 will not exceed 33 million Hong Kong dollars, a decrease of approximately 59% from the same period in 2024 when the attributable loss to owners was 79.917 million Hong Kong dollars. The significant improvement in operating performance is mainly due to the company's successful implementation of cost control measures, resulting in an increase in gross profit margin and a reduction in administrative expenses. The company also received compensation income of approximately 14 million Hong Kong dollars from insurance claims made regarding damage caused by heavy rain in Hainan construction sites in 2024.